Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28699580 | 0.88 | USP2 (0.44) | USP2SMN1; SMN2RECQLHPGDEPHX2 | |
| SCHEMBL23527934 | 0.88 | USP2 (0.46) | USP2SMN1; SMN2RECQLHPGDEPHX2 | |
| SCHEMBL965651 | 0.86 | USP2 (0.51) | USP2SMN1; SMN2RECQLHPGDEPHX2 | |
| SCHEMBL2157135 | 0.86 | USP2 (0.51) | USP2SMN1; SMN2RECQLHPGDEPHX2 | |
| SCHEMBL29993720 | 0.84 | USP2 (0.43) | USP2SMN1; SMN2HPGDEPHX2CYP4F2 | |
| SCHEMBL3970403 | 0.83 | PKM (0.49) | USP2SMN1; SMN2RECQLHPGDEPHX2 | |
| SCHEMBL28986539 | 0.82 | USP2 (0.45) | USP2SMN1; SMN2RECQLHPGDEPHX2 | |
| SCHEMBL963907 | 0.82 | USP2 (0.47) | USP2SMN1; SMN2RECQLHPGDCYP4F2 | |
| SCHEMBL21565392 | 0.81 | CYP4F2 (0.58) | USP2SMN1; SMN2HPGDEPHX2CYP4F2 | |
| SCHEMBL1954007 | 0.81 | USP2 (0.49) | USP2SMN1; SMN2RECQLHPGDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3725787-B1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230348389-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348389-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| CN-116490186-A | Compounds for targeted degradation of RET | C4医药公司 | 2023-07-25 | — | — | CN | disclosed |
| US-11702389-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702389-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-07-18 | — | — | US | disclosed |
| EP-4192458-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-10968180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-10358421-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2019-07-23 | — | — | US | disclosed |
| US-10239837-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180022702-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | ACETYLON PHARMACEUTICALS, INC. | 2018-01-25 | — | — | US | disclosed |
| US-20180022702-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | ACETYLON PHARMACEUTICALS, INC. | 2018-01-25 | — | — | US | disclosed |
| US-20170369441-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2017-12-28 | — | — | US | disclosed |
| US-9790180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160168093-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160168093-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168093-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | USP2 723/4885SMN1; SMN2 1134/4885RECQL 3835/4885 |
| US-20170369441-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | USP2 723/4885SMN1; SMN2 1134/4885RECQL 3835/4885 |
| US-11702389-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | USP2 723/4885SMN1; SMN2 1134/4885RECQL 3835/4885 |
| US-20230348389-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | USP2 723/4885SMN1; SMN2 1134/4885RECQL 3835/4885 |
| US-10968180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | USP2 723/4885SMN1; SMN2 1134/4885RECQL 3835/4885 |
| US-10239837-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | USP2 723/4885SMN1; SMN2 1134/4885RECQL 3835/4885 |
| US-10358421-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | USP2 723/4885SMN1; SMN2 1134/4885RECQL 3835/4885 |
| US-20180022702-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | USP2 723/4885SMN1; SMN2 1134/4885RECQL 3835/4885 |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | RET, HRAS, RBX1 | USP2 237/4885SMN1; SMN2 2460/4885RECQL 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.